All In Biotech

BLA 761148 · Spectrum Pharms

Rolvedon

Eflapegrastim-Xnst · Subcutaneous · Leukocyte Growth Factor

Novel

CDER novel approval, Sep 9, 2022: To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia

Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Sep 9, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9

2 Phase 3, 1 recruiting

FAERS reports

30

16 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 18, 2026.

Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. Rolvedon is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. ( 1 ) Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. ( 1 )

Mechanism: Eflapegrastim-xnst is a recombinant human granulocyte growth factor that binds to G-CSF receptors on myeloid progenitor cells and neutrophils, triggering signaling pathways that control cell differentiation, proliferation, migration and survival.

Therapeutic areas: Oncology · Hematology and blood cancers · Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 9, 2022 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • ROLVEDON · EFLAPEGRASTIM-XNST 13.2MG/0.6ML · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Eflapegrastim" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • white blood cell count increased4
  • asthenia3
  • diarrhoea3
  • leukocytosis3
  • off label use3
  • abdominal pain2
  • accidental exposure to product2
  • bone pain2
  • constipation2
  • fatigue2
  • febrile neutropenia2
  • nausea2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20222
20232
202413
202510
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rolvedon (Eflapegrastim-Xnst)

2024 spending

$1.6M

Beneficiaries

100

345 claims

Per beneficiary

$16,237

$7,197.33 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$661,601
2024$1,623,717

Part B: Rolvedon (Eflapegrastim-Xnst) · HCPCS J1449

2024 spending

$73.8M

Beneficiaries

6,293

21,515 claims

Per beneficiary

$11,721

2024 ASP limit $26.59 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$52,360,428
2024$73,760,786

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: Spectrum Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.